<DOC>
	<DOC>NCT00139919</DOC>
	<brief_summary>This study is to assess the tolerability of bifeprunox with the progressive elimination of titration steps to achieve the shortest tolerated titration dosing to a dose of 40 mg/day in either schizophrenia or bipolar disorder subjects. Study duration is 2 months with an optional open-label 26-week extension study.</brief_summary>
	<brief_title>Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Subjects with the current Diagnosis of Schizophrenia, Bipolar Type I Disorder according to DSMIV TR criteria Age 18 to 55 Body weight 100250 lbs Be sufficiently stable to allow discontinuation of antipsychotic medication Acutely psychotic subjects Subjects that are acutely manic Subjects with a psych diagnosis other than Bipolar Type I Disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Decreasing Titration Study</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Bipolar</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>